Updated on 25 January 2013
Good news for dengue patients – NIH's National Institute of Allergy and Infectious Diseases (NIAID) trial of dengue vaccine TetraVax-DV shows positive results
Singapore: A dengue vaccine candidate developed by the National Institutes of Health (NIH) has shown to be safe and has generated a strong immune response. The early-stage clinical trial was sponsored by NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the results of the study were published in the January 17, 2013, issue of Journal of Infectious Diseases.
NIAID director Dr Anthony S Fauci said that, "We are cautiously optimistic about these recent clinical trial results with this candidate tetravalent vaccine developed at NIAID. However, much more work still needs to be done."
The phase I clinical trial, launched in July 2010 and led by principal investigator Dr Anna Durbin, Johns Hopkins Bloomberg School of Public Health in Baltimore, tested a single dose of each of four versions of the investigational dengue vaccine TetraVax-DV. The vaccine was developed by scientists in NIAID's Laboratory of Infectious Diseases.
It is a live-attenuated vaccine, which means that the viruses it contains are weakened enough such that they do not cause illness but still can induce an immune response. Each of the four vaccines tested included different mixtures of components designed to protect against all four dengue viruses.
The researchers found that all four candidate vaccine combinations induced antibody responses against each of the dengue viruses. However, one vaccine combination, TV003, appeared to induce the most balanced antibody response against the dengue viruses. A single dose of TV003 resulted in an antibody response to all four dengue viruses in 45 percent of participants and against three-of-the-four viruses in an additional 45 percent. Overall, an immune response to at least three viruses was seen in 90 percent of vaccinees given TV003.